# Evaluating COVID-19 reporting data in the context of testing strategies across 31 LMICs

Mollie M. Van Gordon, Ph.D.<sup>1,\*</sup>, Kevin A. McCarthy, Ph.D.<sup>1</sup>, Joshua L. Proctor, Ph.D.<sup>1</sup>, Brittany L. Hagedorn, MBA<sup>1</sup>

### Abstract

### 0.1. Background

COVID-19 case counts are the predominant measure used to track epidemiological dynamics and inform policy decision-making. Case counts, however, are influenced by testing rates and strategies, which have varied over time and space. A method to consistently interpret COVID-19 case counts in the context of other surveillance data is needed, especially for data-limited settings in low- and middle-income countries (LMICs).

### 0.2. Methods

We leverage statistical analyses to detect changes in COVID-19 surveillance data. We apply the pruned exact linear time change detection method for COVID-19 case counts, number of tests, and test positivity rate over time. With this information, we categorize change points as likely driven by epidemiological dynamics or non-epidemiological influences such as noise.

Preprint submitted to medRxiv

February 11, 2021

<sup>\*</sup>Corresponding author: mvangordon@idmod.org; +1 (425) 526-3104

 $<sup>^{1}\</sup>mathrm{Institute}$  for Disease Modeling at the Bill & Melinda Gates Foundation, Seattle, WA, USA

### 0.3. Findings

Higher rates of epidemiological change detection are more associated with open testing policies than with higher testing rates. The non-pharmaceutical intervention most correlated with epidemiological change is workplace closing. LMICs have the testing capacity to measure prevalence with precision if they use randomized testing. Rwanda stands out as a country with an efficient COVID-19 surveillance system. Sub-national data reveal heterogeneity in epidemiological dynamics and surveillance.

### 0.4. Interpretation

Relying solely on case counts to interpret pandemic dynamics has important limitations. Normalizing counts by testing rate mitigates some of these limitations, and open testing policy is key to efficient surveillance. Our findings can be leveraged by public health officials to strengthen COVID-19 surveillance and support programmatic decision-making.

### 0.5. Funding

This publication is based on models and data analysis performed by the Institute for Disease Modeling at the Bill & Melinda Gates Foundation.

# Research in Context

### Evidence before this study

We searched for articles on the current practices, challenges, and proposals for COVID-19 surveillance in LMICs. We used Google Scholar with search terms including "COVID surveillance." Existing studies were found to be qualitative, anecdotal, or highly location-specific.

### Added value of this study

We developed a quantitative method that makes use of limited information available from LMICs. Our approach improves interpretation of epidemiological data and enables evaluation of COVID-19 surveillance dynamics across countries.

# Implications of all the available evidence

Our results demonstrate the importance of open testing for strong surveillance systems, bolstering existing anecdotal evidence. We show strong alignment across LMICs between workplace restrictions and epidemiological changes. We demonstrate the importance of considering sub-national heterogeneity of epidemiological dynamics and surveillance.

# <sup>2</sup> 1. Introduction

The virus known as SARS-CoV-2 was first identified in Wuhan, China in December 2019. Since then, countries have scrambled to monitor the severity and trajectory of the COVID-19 outbreak and to control its progression using non-pharmaceutical interventions (NPIs). Disease surveillance has mostly relied on case counts to inform public health policies.<sup>1</sup> There has not, however, been a robust evaluation of case counts as a metric for epidemiological dynamics, nor the varied surveillance approaches used to track disease trajectories.

<sup>11</sup> Case-based surveillance systems have known weaknesses, including the strong <sup>12</sup> influence of testing rates, which vary widely across space and time.<sup>2</sup> Case

counts can be inconsistently measured, testing capacity limited, and eligibility policies variable. It is critical to understand the limitations of available
data and to identify metrics that are robust to these challenges, particularly
for low- and middle-income countries (LMICs).

There is general recognition that surveillance system performance can be 17 a challenge in LMICs, and that understanding disease surveillance is key 18 to system improvement and production of representative data.<sup>3</sup> Existing ef-19 forts to evaluate LMIC surveillance systems, however, are largely qualitative, 20 country-specific, or based on commentary.<sup>4–6</sup> Further, most national-level 21 studies of NPI impacts focus on high-income countries,<sup>7-11</sup> but there is evi-22 dence that these insights cannot be readily generalized to LMIC settings.<sup>12,2</sup> 23 This leaves an important knowledge gap in understanding how to evaluate 24 and interpret COVID-19 epidemiological data from LMICs. 25

To address the gap in systematic interpretation and evaluation methods, we 26 leverage statistical analysis techniques to detect changes in underlying prop-27 erties of COVID-19 time series surveillance data across 31 LMICs. With this 28 information, we categorize detected change points as likely driven by epi-29 demiological changes or non-epidemiological influences such as noise. This 30 provides a quantitative and automated approach to analyzing epidemiolog-31 ical surveillance data. We make use of imperfect information despite data 32 weaknesses, deriving insights from information available in LMICs that may 33 otherwise be overlooked. The approach is fast and highly portable, well 34 suited to looking across countries, and has minimal data requirements. 35

In this article, we first present the methods for our analysis, including the statistical model, change point categorization, and evaluation of epidemiological change co-occurrence with NPIs. We follow with validation of our method, the usefulness of open testing, comparisons of country surveillance characteristics, and consideration of sub-national dynamics. Finally, we elaborate on the significance of our results, broader conclusions, and relevance for public health applications.

# 43 2. Methods

- <sup>44</sup> The methods are outlined in Figure 1 for two example countries: South Africa
- and Bangladesh. Details about each step are presented in the following sub-sections.



Figure 1: Methods Overview. Time series for cases (orange), tests (blue) and positivity (green) for case study countries South Africa and Bangladesh. Vertical lines indicate detected change points on each series. National changes in testing policy are shown as blue bars; see Section 2.1 for policy descriptions. Positivity change points are overlaid with case and test changes. Change points from the three time series are grouped in time; shading on positivity changes indicates grouping tolerance. Category labels for change point groups are shown above positivity and described in Figure 2. Black arrows indicate NPI changes; arrow direction indicates increase or decrease in stringency. For categories D and E, Y(es) and N(o) in boxes below positivity indicate whether there is a co-occurring NPI change inverse to the change in slope of positivity.

### 47 2.1. Data

We use national-level case and testing data as well as records on national 48 policies for testing and NPIs.<sup>13,14</sup> We calculate test positivity by dividing 49 case rate by test rate. Testing policy is indicated by ordinal values: zero 50 indicates no testing policy; one indicates testing of those with symptoms 51 who meet specific criteria (e.g. known contact with a positive individual); 52 two indicates testing of any symptomatic individuals; three indicates open 53 public testing. For South Africa, we also use provincial-level data on COVID-54 19-confirmed deaths, cases and testing rates, and excess mortality.<sup>15-18</sup> 55

We selected countries for analysis based on three conditions: available case data, available testing data, and human development index (HDI) score. Of those with data, we included the countries in the lowest third of HDI score, all of which are considered low- or middle-income in 2020-2021 by the World Bank. All data used in this research are public. Further details on data and definitions found in Appendix A.1.

# 62 2.2. Change point detection

### 63 2.2.1. Pruned Exact Linear Time (PELT) change detection

Change point detection is a set of approaches for identifying points in time 64 where the statistical properties of a time series change.<sup>19</sup> We apply change 65 point detection to epidemiological time series (cases, tests, and positivity) 66 and national policy time series; details in Appendix A.2. Without a priori 67 knowledge of the appropriate number of changes, the PELT algorithm must 68 be assigned a penalty for the number of changes to identify. In the absence of an established method for this parameterization when working across time 70 series, we developed a novel systematic approach for penalty selection which 71 enables comparison among time series and countries; described in Appendix 72 A.3. 73

#### 74 2.2.2. Method validation

<sup>75</sup> We applied PELT to synthetic data generated by the stochastic agent-based
 <sup>76</sup> Epidemiological Modeling software (EMOD),<sup>20</sup> verifying PELT as a robust

method for change detection in epidemiological time series. The EMOD 77 model used for our validation analysis is parameterized to represent transmis-78 sion characteristics in Ethiopia. The model scenario inputs include step-wise 70 increases in social distancing stringency, along with temporary decreases in 80 stringency representing immunization campaigns. The model outputs a sim-81 ulated time series of cases per thousand people. The change point detection 82 methods described above are applied to the seven-day mean of the case rate 83 time series to align with the data smoothing used with our empirical time 84 series. 85

### <sup>86</sup> 2.3. Change type categorization

<sup>87</sup> Change detection identifies changes that may be related to data quality,
<sup>88</sup> stochasticity, and testing dynamics, in addition to epidemiological changes.
<sup>89</sup> We classify the likely cause of changes identified by the PELT algorithm based
<sup>90</sup> on which changes co-occur. This categorization simplifies the interpretation
<sup>91</sup> of epidemiological surveillance, separates signal from noise, and enables broad
<sup>92</sup> comparison across countries and testing dynamics.

We combine detected change points across cases, tests, and positivity time 93 series to create change point groups. The tolerance for temporal association 94 is set at  $\pm$  seven days to account for seven-day smoothing and weekly data 95 reporting practices. These change groups are then categorized as shown in 96 Figure 2, with details of the interpretation described in Appendix B. To 97 capture all changes that may be epidemiological, we include both categories 98 D and E as epidemiological change in our analysis. We note that these cate-99 gories are heuristically defined, however they are informed both by validation 100 using the EMOD simulations and a qualitative understanding of epidemio-101 logical surveillance dynamics. 102

Label	Constituent time series	Description	Origin
(A)	С / Т / Р	Single variable change	Data issues/noise
<b>(B)</b>	С + Т	Cases and tests move together	Likely non-epi
(C)	<b>T</b> + P	Tests drive positivity change	Likely non-epi
(D)	C + P	Cases drive positivity change	Likely epi
(E)	C + T + P	Cases, tests, positivity change	Confounded

Figure 2: Summary of change group categories as determined by their constituent time series changes. Cases, tests, and positivity time series are indicated as orange, blue, and green, respectively. Details of the category interpretations are described in Appendix B.

### 103 2.4. NPI alignment

Change points classified as epidemiological are then assessed for whether they 104 are associated with NPI changes. Timings of known NPIs are lagged by nine 105 days to account for virus incubation time and the delay from symptom onset 106 to test-seeking.<sup>21</sup> We consider a change point to be aligned with an NPI when 107 two conditions are met: 1) an epidemiological change co-occurs with an offset 108 NPI and 2) the change in NPI stringency is inverse to the concurrent change 109 in positivity slope. The second condition includes occasions when stringency 110 was increased and positivity decreased, as well as occasions when stringency 111 decreased and positivity increased. 112

### 113 3. Results

# <sup>114</sup> 3.1. Synthetic modeling validates Pruned Exact Linear Time (PELT) is a <sup>115</sup> robust method for change detection in epidemiological time series.

Before applying the PELT method to the surveillance data, we validate its applicability for epidemiological systems. We apply PELT change detection to data from the transmission model described in Section 2.2.2. PELT successfully identifies step changes in NPI policies and slope changes in case rate, Figure 3.

While detection of NPI changes is consistent across a range of PELT penal-121 ties, change point detection is sensitive to parameterization when applied to 122 the case rate time series, Figure 3B. When implemented with a high penalty 123 (i.e. fewer change points), the PELT algorithm successfully identifies changes 124 corresponding to the large-scale social distancing policies and changes in the 125 basic shape of the case curve. With this penalty, it does not detect the rela-126 tively transient effects of the immunization campaigns. When parameterized 127 with a low penalty (i.e. more change points), the PELT algorithm identifies 128 the immunization campaigns as well. 120



Figure 3: Synthetic model time series; detected change points shown as vertical dotted lines. A) Imposed policy inputs to model: social distancing (purple) and immunization campaigns (brown). Short-term immunization campaigns represented by a switch in the immunization time series from one to zero. B) Model output: case rates over time. Upper plot shows detected change points using a high penalty, thereby promoting sparse change point detection. Lower plot shows detected change points using a low sparsity penalty.

# 3.2. Testing rates and policies impact how surveillance measures should be interpreted.

We illustrate the relevance of testing rates and the influence of testing policy using time series for Bangladesh in the context of local events (Figure 1). Case rates peaked in early July, an apparent epidemiological turning point if case rates were considered alone. Simultaneously, however, there was a new

policy implemented to charge for testing and thus a decline in testing rate.<sup>22</sup>
This resulted in no change in positivity and contradicts the interpretation of
the case reduction as a declining outbreak. Similarly, the dip in case rate in
early August was accompanied by a dip in testing rate during the Eid al-Fitr
holiday; again there is no change in positivity.

While this recommends positivity as a surveillance metric instead of case 141 counts alone, further consideration of testing policy complicates the picture. 142 Test eligibility in Bangladesh is based on symptoms rather than open testing, 143 meaning that positivity is influenced by the prevalence of both COVID-19 144 and other respiratory illnesses. This limits the potential for positivity to de-145 tect epidemiological changes, and indeed, the positivity curve for Bangladesh 146 is largely flat. An elaboration of COVID-19 surveillance considerations ap-147 pears in Appendix C. 148

# 3.3. Epidemiological change detection is more influenced by testing policy than by testing rate.

For all 31 LMICs in our dataset, we apply PELT change detection and change 151 point categorization. We quantify surveillance system efficiency as the per-152 centage of all detected change points classified as epidemiological, i.e. epi-153 demiological change detection rate. We compare linear fits of epidemiological 154 change detection by testing rate and by testing policy (Figure 4). Results 155 indicate that the ability to identify epidemiological changes has a stronger 156 relationship with testing policy than with testing rate. Open testing is the 157 only testing policy bin with a mean or median epidemiological change detec-158 tion rate as high as 50%, but with a wide range, indicating that open testing 159 policy is necessary but not sufficient for quality surveillance (with outlier 160 exceptions). 161



Figure 4: Percent of detected changes categorized as epidemiological for each country by testing rate (left) and binned by testing policy (right) at the time of change detection. Linear regression shown as dotted line on left. Box and whisker plots on right show quartiles, range, and median with means plotted as gray diamonds. Note that binned calculations cause the maximum epidemiological change detection rate to differ between the two plots.

Further, LMICs have the testing capacity to measure prevalence with pre-162 cision. Based on the 95th percentile of their daily testing rates, nearly all 163 LMIC countries could measure down to 1% prevalence with a margin of er-164 ror no larger than  $\pm 1\%$  if testing were randomly sampled (Figure 5). Only 165 three countries hover around the margin of error to prevalence ratio of one: 166 Malawi, the Democratic Republic of Congo, and Togo. Note that true ran-167 dom sampling is difficult to achieve in any setting, but open testing policies 168 can approximate random sampling more closely than symptomatic testing. 169



Figure 5: Margin of error for random sampling of 1% prevalence plotted by 95th percentile of national testing rate and population of each country in our dataset. See Appendix D for details on standard error calculations.

### <sup>170</sup> 3.4. Change detection rates and NPI alignment frequency vary across LMICs.

Figure 6 shows frequencies of change category detection across countries. Rwanda is an outlier with high epidemiological detection accompanied by low non-epidemiological and noise detection rates. High rates of noise detection are generally associated with low rates of epidemiological change detection, whereas the relationship between noise detection and non-epidemiological change detection is not consistent.



Figure 6: Change type ratios by country. The sum of categories D and E (considered epidemiological changes) normalized by the total number of changes per country on the y-axis. Category B (non-epidemiological) change detection rate on x-axis. Category A (noise-related) change detection rate shown in color.

Figure 7A shows the wide variation of epidemiological change detection rates across LMIC countries, with Rwanda the highest and Ethiopia the lowest. The percentage of NPIs that are aligned with an epidemiological change is shown in Figure 7B, again led by Rwanda. Note that Rwanda performs well by these metrics regardless of change detection parameterization, Appendix A.4.



Figure 7: Epidemiological change detection rates (A) and NPI alignment rates (B) by country.

### <sup>183</sup> 3.5. Alignment with detected epidemiological changes varies by NPI type.

The NPIs most frequently aligned with epidemiological changes are workplace closures, public transport closures, and stay at home requirements. The percentage of these NPIs that are aligned with epidemiological changes are 15.1%, 14.3%, and 12.2%, respectively. Note that there are substantially fewer total public transit NPIs than workplace closures and stay at home

requirements. Cancelling public events has the lowest frequency of epidemiological alignment at 6.12%, and also the fewest number of implementation
incidences.



Figure 8: The percentage of each type of NPI aligned with an epidemiological change. Color indicates the total number of each type of NPI across all countries; error bars show standard error. NPIs include both easing and tightening of policy restrictions.

# 3.6. National-level results obscure sub-national heterogeneity in epidemiolog ical dynamics and surveillance.

To investigate sub-national heterogeneity, we conduct the same analyses as above, but at the province level in South Africa. Figure 9A shows substantial variability in provinces both by NPI alignment rate and by epidemiological change detection rate. In line with results from national-level data, epidemiological change detection rate is not correlated with mean testing rate. Because of reporting limitations, the NPIs here are national policies only.

<sup>200</sup> We select three edge cases from the scatter plot in Figure 9A (Limpopo,

Northern Cape, and Western Cape) to compare time series of positivity,
COVID-19-confirmed deaths, and total estimated excess mortality (Figure 9B). The differences in the timing and trajectories of the time series illustrate
strong sub-national variability in underlying epidemiological dynamics that
are may be overlooked when time series are aggregated to the national level.

Variation among provinces in the difference in magnitude between excess mortality and COVID-19 deaths points to differences in their surveillance systems. Western Cape is the only province where the magnitude of excess deaths resembles that of COVID-19-confirmed deaths throughout the time series. In Northern Cape, the peak of excess deaths is roughly a factor of three higher than the COVID-19-confirmed deaths, suggesting substantial under-reporting.



Figure 9: A) South African provinces by aligned NPI fraction versus epidemiological detection rate with mean testing rate in color. B) Time series from three example provinces. Positivity shown in green on left y-axis. Deaths shown on the right y-axis: excess mortality in black; COVID-19-confirmed deaths in brown.

### 213 4. Discussion

We have demonstrated a standardized and quantitative approach to ana-214 lyzing epidemiological surveillance time series that can be automated for 215 improved interpretation and comparison between countries. We find that in-216 terpretation of epidemiological trajectories are more informative when cases 217 are normalized by tests and highlight the disadvantages of symptomatic test-218 ing for outbreak tracking and public health purposes. These findings align 219 with literature emphasizing the importance of positivity and test sampling 220 strategies.<sup>23,24</sup> Our finding of a strong alignment of workplace closing with 221 epidemiological changes is consistent with existing literature on global NPI 222 impacts.<sup>12,25,26</sup> When we apply our analysis of change types to evaluate the 223 efficiency of national surveillance systems, we find that Rwanda stands out as 224 a country with a strong surveillance system, which is consistent with current 225 qualitative evaluation.<sup>27</sup> 226

Our approach substantially broadens the scope of previous analyses of COVID-227 19 surveillance data in LMICs. We use statistical change detection methods 228 on COVID-19 surveillance time series from 31 LMICs to differentiate epi-229 demiological changes from changes related to stochasticity, data quality and 230 non-epidemiological dynamics. This maximizes the insights gained from lim-231 ited data, reduces erroneous interpretations of epidemiological time series, 232 and enables quantitative comparisons of disease surveillance approaches. We 233 use epidemiological change detection rate as a proxy for surveillance system 234 efficiency, and show that epidemiological change detection is not as strongly 235 associated with testing rate as with open testing policies. There is substan-236 tial variation in epidemiological and surveillance dynamics across countries 237 and in our sub-national analysis. 238

There are limitations in our analysis related to the data themselves as well 239 as our methods. Simultaneously, these data challenges are precisely the mo-240 tivation for developing our methods: maximizing information with limited 241 data. Our data are potentially biased by unmeasured factors such as fluctu-242 ations in testing capacity and undocumented population sampling strategies 243 over time, delays and temporal uncertainty due to reporting systems, and 244 incentives for case-finding. Defining co-occurrence when working with im-245 precise time series is a challenge, which we partially mitigate by considering 246 uncertainty bounds when defining change groups. We emphasize, of course, 247

that co-occurrence does not establish causality. In PELT change detection,
the changes detected are influenced by the choice of the sparsity parameter.
In a sensitivity analysis of our novel parameterization approach, however,
we find that Rwanda remains the leader in surveillance system performance,
regardless of the parameterization choice.

Results from this analysis highlight that surveillance data must be used care-253 fully to ensure proper programmatic responses. As a sufficient and less 254 resource-intensive approximation of random sampling, open testing would 255 enable better estimation of disease prevalence and examination of NPI im-256 pacts in geographies without reliable hospitalization data, death records, or 257 seroprevalence surveys. NPIs without epidemiological changes may indicate 258 inefficacy of policy, but may also indicate shortfalls of surveillance systems, 259 which undermines policy makers' ability to make evidence-based decisions. 260 Our methods could be further developed and applied not just to COVID-19 261 but also to surveillance interpretation for other poorly measured diseases, en-262 abling more informed decision-making and targeted improvements in surveil-263 lance systems. 264

# <sup>265</sup> 5. Declarations

### 266 5.1. Declaration of interests

<sup>267</sup> The authors declare no conflicts of interest.

### <sup>268</sup> 5.2. Role of funding source

This publication is based on models and data analysis performed by the Institute for Disease Modeling at the Bill & Melinda Gates Foundation. The funder had no influence on the analysis or conclusions presented here.

# 272 Appendix A. Methods

### 273 Appendix A.1. Data and definitions

The case rate is defined as the number of individuals confirmed positive for the SARS-CoV-2 virus per population, regardless of symptoms. The testing rate per population is defined as the number of people tested (i.e. excluding duplicate confirmatory tests) divided by the population, regardless of the test outcome. To address the dependence of case rate on testing rate, we normalize case counts by the number of tests conducted, creating the alternate metric of test positivity rate.

For the purposes of comparing between countries and over time, we define the 281 'mean testing policy' as the average over time of the ordinal value represent-282 ing the national testing policy. Thus, lower values represent more restricted 283 testing over longer periods of time. Social distancing policies tracked in the 284 dataset include the following: closing schools, closing workplaces, cancelling 285 public events, restricting gathering sizes, closing public transport, stay at 286 home requirements, restricting in-country mobility, and restricting interna-287 tional travel. 288

Weekly cases, testing, and death data are interpolated using a cubic spline. All daily cases, testing and death data are smoothed using a centered sevenday rolling average. Error bars on plots show standard error.

### <sup>292</sup> Appendix A.2. PELT change detection

The naive approach to generating an exact solution to time series segmentation is to test all possible solutions. For an unknown number of changes, this also requires testing a sufficiently large set of possible number of changes. We use the Pruned Exact Linear Time (PELT) change detection method to address these computational tractability issues.

PELT minimizes the sum of costs from a criterion function across time series
segments while balancing model complexity by implementing a linear penalty
function and change point pruning. At each iteration of cost minimization for
a potential set of change points, time points that cannot be a global minima

are removed from future consideration. The PELT method, developed with
 applications in genetics and finance in mind, is increasingly used for climate
 and epidemiological applications.<sup>28-30</sup>

To detect changes in slope of the epidemiological time series, we use the first derivative as input for the PELT algorithm. For detection of discrete step changes of policy time series, we feed the data directly into the change detection algorithm without taking a derivative. For all time series, we use the radial basis function kernel for the PELT detection algorithm.

### 310 Appendix A.3. PELT parameterization

To date, there is no established method for parameterizing the PELT change density penalty across time series when the number of changes is not known. One of the ways to choose penalty values across time series would be to unify the number of changes detected in each time series. This, however, imposes the assumption that all time series exhibit the same general change frequency and it is only the point in time of a change that is unknown, rather than the number of changes.

We present here a novel approach for systematic parameterization when iden-318 tifving an unknown number of changes in slope over many time series, as in 319 our case with multiple epidemiological time series across countries. To ac-320 complish this, we first conduct change detection in a sweep over parameter 321 space. The change points detected using a given value in parameter space 322 slice the time series into segments, each of which is input into a linear re-323 gression. The standard error for each of those linear regressions is calculated 324 and then averaged, weighted by segment length. 325

The mean standard error associated with each penalty value, when plotted over parameter space, is characterized by a series of plateaus that correspond to plateaus in the number of changes found with each penalty value, Figure A.10, top row. Descending through penalty values in the penalty parameter space, the lowest penalty associated with each plateau is selected to represent that plateau.

Each time series is thus associated with a sparse set of penalty values, ordered from largest penalty (low change point density) to smallest penalty (high

change point density). The penalty values are unique to each time series,
but represent the same ordered progression of plateaus. To illustrate, change
detection with different ranked penalties for South Africa and Bangladesh
are shown in green in Figure A.10.

Penalty values for each unique time series can then be chosen based on their order in the ranked plateau list. This enables a principled approach to parameterization that creates change density parity across time series, allowing for the likelihood that some time series are characterized by more changes than others. Among all time series and countries in our analysis, the minimum number of plateaus detected is four. We therefore choose the fourth penalty value for all time series.



Figure A.10: Top row: change detection results over parameter space for the positivity time series of South Africa (left) and Bangladesh (right). For each penalty value, the associated number of changes is plotted in purple on the left y-axis and the mean standard error of linear regressions of the time series segments are plotted on the right y-axis. The parameter values selected to represent plateaus are shown as brown dotted vertical lines. Bottom row: positivity time series for South Africa (left) and Bangladesh (right) plotted with detected changes as vertical lines for each of the four penalty values selected to represent plateaus in the top row.

### 345 Appendix A.4. Parameterization sensitivity analysis

To evaluate the influence of penalty selection on our analysis results, we conduct a parameterization sensitivity analysis. We compare results of country

ranking by epidemiological change detection rate for different penalty plateau
selections. Skipping penalty rank one for which no changes may be detected
(see examples in Figure A.10), we find that regardless of which penalty rank
we use, Rwanda appears at the top of the list with the highest epidemiological
change detection rate.



Figure A.11: Countries ranked by epidemiological change detection rate, as in Figure 7, shown for different choices of penalty parameterization. Order top to bottom follows order of time series of Figure A.10, without rank one for which there are often no changes.

# 353 Appendix B. Change categorization

### <sup>354</sup> Appendix B.1. Heuristic interpretation

Detected change points across cases, testing, and positivity time series are combined into groups by temporal co-occurrence. These groups are then categorized by their constituent time series, Figure 2. Dynamical interpretation of the constituent time series aids in the characterization of each change group category, as follows:

A) Single variable change: Because positivity is defined according to the 360 arithmetic relationship, Positivity = Cases/Tests, a change in any one 361 of the variables should be accompanied by a change in at least one of the 362 other variables. A single change in only one of the variables indicates that 363 the change arises from issues in the data or noise. These single variable 364 changes often occur early in the time series, when the numbers of cases 365 and tests are smaller, signal to noise ratios are lower, and confidence 366 intervals are larger. 367

B) Cases and tests change: Tests and cases move up or down together. 368 What might look like a significant change in cases is associated with a 369 change in testing, likely not a change in epidemiology. Factors affecting 370 testing include testing capacity, care-seeking behavior, and testing sam-371 pling policy. With this change category, the change in testing could be 372 a change in capacity or care-seeking, but the lack of change in positiv-373 ity indicates testing is still sampling the same population the same way, 374 without changes in epidemiology. 375

Tests and positivity change: Positivity change is driven by testing change, C) 376 not a change in cases. An increase or decrease in testing does not impact 377 absolute numbers of detected cases, which suggests a change in test sam-378 pling. Dynamics that would produce this pattern include, for example, 379 adding population with lower prevalence in the case of open testing, or 380 limiting testing to a higher-prevalence population in the case of symp-381 tomatic testing. It is also possible, however, that a change in testing 382 sampling masks a simultaneous change in epidemiology. In this situa-383 tion, the change in testing would have to precisely offset the change in 384 epidemiology to observe this category of change association. Category C 385 is thus designated to likely indicate a non-epidemiological change. 386

D) Cases and positivity change: Positivity change is driven by a change in 387 cases without a change in testing. This suggests a change in epidemiology, 388 but the significance may be different under random vs. symptomatic test-389 ing. Under random testing, this type of change arises only with a change 390 in SARS-CoV-2 epidemiology. Under symptomatic testing, the restric-391 tion of sampling to CLI means that a change in the epidemiology may 392 be confounded by a change in CLI epidemiology. Note also that symp-393 tomatic testing captures changes only in symptomatic SARS-CoV-2 (i.e. 394 cases of COVID-19). Another possible explanation for this combination 395 of changes is a change in sampling without a change in the absolute num-396 ber of tests. This might occur, for example in a switch from symptomatic 397 to open testing. For this reason, we categorize this change combination 398 as likely instead of certainly epidemiological. 399

E) All three variables change: With a change in cases, tests, and positivity, it remains difficult to disentangle epidemiological from non-epidemiological factors. Category E can be considered a combination of categories C and D, and the testing and case changes may or may not be independent. To capture all changes that may be epidemiological, we consider categories D and E to be epidemiological changes, and categories A, B, and C to be non-epidemiological changes.

<sup>407</sup> A principal component analysis (PCA) supporting the separability of change<sup>408</sup> categories is detailed in Appendix B.2.

# 409 Appendix B.2. PCA analysis of change categories



Figure B.12: PCA of countries by change category detection rate (i.e. number of changes in each category divided by total changes detected for each country). A) Explained variance ratio by PCA component number; B) PCA factor loadings by change categories.

In addition to the dynamical interpretation of constituent time series (Appendix B), we show the separability of change categories with a principal component analysis (PCA). The surveillance results of different countries are quantitatively characterized by a PCA of the relative frequency with which they detect different categories of changes. The PCA establishes how categories do or don't represent axes of difference across countries.

Based on the curve of explained variance ratio by PCA components (Figure 416 B.12A), we choose the first three PCA components to examine factor loadings 417 (Figure B.12B). Each component is dominated by a single category, in PCA 418 component order: category D (epidemiological change); category B (testing 419 artifacts); and category E (confounded). Each of these PCA components 420 is anti-correlated with category A (noise). These relationships among the 421 different change categories is consistent with our dynamical interpretation. 422 Figure B.13 shows the frequencies of change categories for those categories 423 that dominate the factor loadings for all countries in our dataset. 424



Figure B.13: Change category frequencies by country for categories D, B, and E, chosen according to the dominant categories in the PCA factor loadings.

### 425 Appendix C. Surveillance considerations

Below we lay out in basic terms considerations for three components of SARS-CoV-2 epidemiological surveillance: population, testing, and their role in surveillance metrics. We demonstrate that the testing strategy of random testing with the surveillance metric of positivity is the combination that best represents SARS-CoV-2 prevalence. Here we use the terminology of SARS-CoV-2 to include all asymptomatic and symptomatic infections.

<sup>432</sup> Population is composed of people with and without SARS-CoV-2. Of those
<sup>433</sup> with SARS-CoV-2, some are asymptomatic, some are symptomatic. Of those

without SARS-CoV-2, some are non-symptomatic, others have symptoms of
non-COVID-like-illness, and some have COVID-like-illness (CLI) symptoms.

Relevant components of testing include eligibility for testing under a given
testing framework, as well as testing rate and capacity. Under random sampling, the general population is eligible for testing; symptomatic testing restricts eligibility to people with CLI symptoms. Testing rate is a measure
of tests conducted per total population, while testing capacity indicates the
proportion of eligible individuals who are actually tested.

<sup>442</sup> Detected cases as a surveillance metric is a function of number of tests, the
<sup>443</sup> eligible testing pool, and the total cases within the testing pool. Positivity
<sup>444</sup> is defined as detected cases per tests conducted.

Applying these formulations to surveillance metrics, we can see that detected
cases under symptomatic testing is not only a function of number of tests
conducted, but also of the number of individuals exhibiting CLI symptoms.
CLI in turn is a function of non-SARS-CoV-2 CLI and symptomatic SARSCoV-2.

Positivity under symptomatic testing is normalized for number of tests conducted, measuring not general prevalence in the population, but the portion
of CLI that is symptomatic COVID-19. Metrics derived from symptomatic
testing do not account for asymptomatic SARS-CoV-2 and are confounded
by non-SARS-CoV-2 CLI.

As with symptomatic testing, detected cases under random testing are a function of number of tests. The sampling, however, is taken from the general population, and thus positivity under random testing is a metric that represents prevalence.

As tests approach eligible under symptomatic testing, cases detected equals
CLI COVID-19 cases. Note, however, that testing coverage (i.e. tests/eligible)
is not only influenced by the number of tests processed, but also reporting
rate. Who shows up for testing is a subset of the people who would be eligible
for testing.

Assuming capacity to test all eligible individuals and perfect reporting rates,
symptomatic testing would still yield only the number of symptomatic COVID-

<sup>466</sup> 19 cases. For random testing, testing rate is equivalent to testing coverage, <sup>467</sup> and case counts depends on testing. The random testing positivity metric <sup>468</sup> does not depend on testing rate, and captures both symptomatic and asymp-<sup>469</sup> tomatic COVID. The relationship shown empirically in Section 3.3 wherein <sup>470</sup> increasingly open testing policies are associated with increasingly effective <sup>471</sup> epidemiological change monitoring supports the equation-based result that <sup>472</sup> random testing is more suited to epidemiological surveillance.

Population components:

 $\begin{aligned} Population &= SARS-CoV-2 + Non-SARS-CoV-2\\ SARS-CoV-2 &= SARS-CoV-2_{asympt} + SARS-CoV-2_{sympt}\\ Non-SARS-CoV-2 &= Non-SARS-CoV-2_{non-sympt}\\ &+ Non-SARS-CoV-2_{sympt\_non-CLI}\\ &+ Non-SARS-CoV-2_{sympt\_CLI}\end{aligned}$ 

Testing components:

$$\begin{split} Eligible_{rand} &= Population = SARS-CoV-2 + Non-SARS-CoV-2 \\ Eligible_{sympt} &= CLI = Non-SARS-CoV-2_{sympt\_CLI} + SARS-CoV-2_{sympt} \\ testing\_rate &= Tests/Population \\ testing\_coverage = Tests/Eligible \end{split}$$

Surveillance metrics:

$$Cases_{total} = SARS - CoV - 2$$

$$Cases_{detected} = Tests * \frac{Cases}{Eligible}$$

$$Positivity = \frac{Cases_{detected}}{Tests} = \frac{Cases}{Eligible}$$

Symptomatic testing:

 $\begin{aligned} Cases_{detected\_sympt} &= Tests_{sympt} * \frac{Cases_{sympt}}{CLI} \\ Positivity_{sympt} &= \frac{Cases_{sympt}}{CLI} \end{aligned}$ 

Random testing:

$$\begin{aligned} Cases_{detected\_rand} &= Tests_{rand} * \frac{Cases_{total}}{Population} \\ Positivity_{rand} &= \frac{Cases_{total}}{Population} = Prevalence \end{aligned}$$

# 473 Appendix D. Summary statistics

For the purposes of understanding the sensitivity of a given level of testing, we define the standard error for positivity, as number of positive tests per total number of tests, we calculate standard error as follows:

$$SE = \sqrt{\frac{p(1-p)}{N} * \frac{N-n}{N-1}}$$

Where n equals total number of tests, N equals population, and p equals the number of positive tests per the total number of tests. The corresponding margin of error equals one-half the confidence interval, and when calculated at the 95% confidence level is as follows:

$$ME(95\%) = 1.96 * SE$$

Note that this formulation of confidence interval is not reliable when number 481 of tests is very small, or probabilities are very close to zero or one. Un-482 der the condition of true random testing, positivity is a direct measure of 483 prevalence. At any given prevalence, margin of error can be calculated for 484 the number of tests administered and the total population. This calcula-485 tion is carried out for all LMIC countries in our dataset. Margin of error is 486 then normalized by the given prevalence rate. Based on these relationships. 487 ME(95%)/Prevalence is higher at lower prevalence. In other words, precise 488 measurement becomes increasingly more difficult as prevalence decreases. 480

### 490 References

- <sup>491</sup> [1] WHO, COVID-19 Weekly Epidemiological Update, 15 Dec, 2020.
- [2] N. Haider, A. Y. Osman, A. Gadzekpo, G. O. Akipede, D. Asogun,
  R. Ansumana, R. J. Lessells, P. Khan, M. M. A. Hamid, D. YeboahManu, et al., Lockdown measures in response to COVID-19 in nine
  sub-Saharan African countries, BMJ Global Health 5 (2020) e003319.
- [3] C. A. Petti, C. R. Polage, T. C. Quinn, A. R. Ronald, M. A. Sande, Laboratory medicine in Africa: A barrier to effective health care, Clinical
  Infectious Diseases 42 (2006) 377–382.
- [4] N. K. Ibrahim, Epidemiologic surveillance for controlling COVID-19
   pandemic: types, challenges and implications, Journal of Infection and
   Public Health 13 (2020) 1630–1638.
- [5] M. Farahbakhsh, A. Fakhari, H. Azizi, E. Davtalab-Esmaeili, Structure, characteristics and components of COVID-19 surveillance system, Journal of Military Medicine 22 (2020).
- [6] N. A. Alwan, Surveillance is underestimating the burden of the COVID 19 pandemic, The Lancet 396 (2020) e24.
- J. M. Brauner, S. Mindermann, M. Sharma, D. Johnston, J. Salvatier,
  T. Gavenčiak, A. B. Stephenson, G. Leech, G. Altman, V. Mikulik,
  et al., Inferring the effectiveness of government interventions against
  COVID-19, Science (2020).

- [8] S. Flaxman, S. Mishra, A. Gandy, H. J. T. Unwin, T. A. Mellan, H. Coupland, C. Whittaker, H. Zhu, T. Berah, J. W. Eaton, et al., Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe, Nature 584 (2020) 257–261.
- [9] S. Hsiang, D. Allen, S. Annan-Phan, K. Bell, I. Bolliger, T. Chong,
  H. Druckenmiller, L. Y. Huang, A. Hultgren, E. Krasovich, et al., The
  effect of large-scale anti-contagion policies on the COVID-19 pandemic,
  Nature 584 (2020) 262–267.
- [10] J. Dehning, J. Zierenberg, F. P. Spitzner, M. Wibral, J. P. Neto,
   M. Wilczek, V. Priesemann, Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions, Science 369 (2020).
- [11] X. Chen, Z. Qiu, Scenario analysis of non-pharmaceutical interventions
   on global COVID-19 transmissions, COVID Economics (2020). ArXiv:
   2004.04529.
- [12] N. Islam, S. J. Sharp, G. Chowell, S. Shabnam, I. Kawachi, B. Lacey,
  J. M. Massaro, R. B. D'Agostino, M. White, Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment
  in 149 countries, BMJ 370 (2020) m2743.
- [13] M. Roser, H. Ritchie, E. Ortiz-Ospina, J. Hasell, Coronavirus pandemic
   (COVID-19) (2020).
- [14] T. Hale, T. Boby, N. Angrist, E. Cameron-Blake, L. Hallas, B. Kira,
  S. Majumdar, A. Petherick, T. Phillips, H. Tatlow, et al., Oxford
  COVID-19 government response tracker (2020).
- <sup>534</sup> [15] Z. Mkhize, Latest confirmed cases of COVID-19 in South Africa (1 nov <sup>535</sup> 2020) (2020).
- [16] National Institute for Communicable Diseases, Weekly testing summary
   (2020).
- <sup>538</sup> [17] Statistics South Africa, P0302 mid-year population estimates, 2020 (2020).
- <sup>540</sup> [18] D. Bradshaw, R. Laubscher, R. Dorrington, P. Groenewald, T. Moultrie,
  <sup>541</sup> Report on weekly deaths in South Africa (2020).

- [19] C. Truong, L. Oudre, N. Vayatis, Selective review of offline change
  point detection methods, Signal Processing 167 (2020) 107299. ArXiv:
  1801.00718.
- [20] A. Bershteyn, J. Gerardin, D. Bridenbecker, C. W. Lorton, J. Bloedow,
  R. S. Baker, G. Chabot-Couture, Y. Chen, T. Fischle, K. Frey, et al.,
  Implementation and applications of EMOD, an individual-based multidisease modeling platform, Pathogens and Disease 76 (2018).
- <sup>549</sup> [21] J. Qin, C. You, Q. Lin, T. Hu, S. Yu, X.-H. Zhou, Estimation of incubation period distribution of covid-19 using disease onset forward time: A novel cross-sectional and forward follow-up study, Science Advances 6 (2020) eabc1202.
- [22] S. Cousins, Bangladesh's COVID-19 testing criticised, The Lancet 396
   (2020) 591.
- [23] N. Pearce, J. P. Vandenbroucke, T. J. VanderWeele, S. Greenland, Accurate statistics on COVID-19 are essential for policy guidance and decisions, American Journal of Public Health 110 (2020) 949–951.
- L. H. Hilborne, Z. Wagner, I. Cabreros, R. H. Brook, Linking statistics
  with testing policy to manage COVID-19 in the community, American Journal of Clinical Pathology 154 (2020) 142–148.
- [25] N. Haug, L. Geyrhofer, A. Londei, E. Dervic, A. Desvars-Larrive,
  V. Loreto, B. Pinior, S. Thurner, P. Klimek, Ranking the effectiveness of worldwide COVID-19 government interventions, Nature Human
  Behaviour 4 (2020) 1303–1312.
- [26] Y. Liu, C. Morgenstern, J. Kelly, R. Lowe, C. C.-. W. Group,
  M. Jit, The impact of non-pharmaceutical interventions on SARS-CoV2 transmission across 130 countries and territories, medRxiv (2020)
  2020.08.11.20172643.
- <sup>569</sup> [27] WHO Regional Office, Africa, COVID-19 in Rwanda: A country's re <sup>570</sup> sponse, WHO Regional Office for Africa (2020).
- [28] R. Killick, P. Fearnhead, I. A. Eckley, Optimal detection of changepoints
  with a linear computational cost, Journal of the American Statistical
  Association 107 (2012) 1590–1598. ArXiv: 1101.1438.

- <sup>574</sup> [29] M. S. Sissoko, K. Sissoko, B. Kamate, Y. Samake, S. Goita, A. Dabo,
  <sup>575</sup> M. Yena, N. Dessay, R. Piarroux, O. K. Doumbo, et al., Temporal
  <sup>576</sup> dynamic of malaria in a suburban area along the Niger River, Malaria
  <sup>577</sup> Journal 16 (2017) 420.
- [30] B. Ouedraogo, Y. Inoue, A. Kambiré, K. Sallah, S. Dieng, R. Tine,
  T. Rouamba, V. Herbreteau, Y. Sawadogo, L. S. L. W. Ouedraogo,
  et al., Spatio-temporal dynamic of malaria in Ouagadougou, Burkina
  Faso, 2011–2015, Malaria Journal 17 (2018) 138.